Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy

Journal of Immunological Methods

Volumn 345, Issue 1-2, 2009, Pages 90-99

  Klapper, Jacob A ^a   Thomasian, Armen A ^a   Smith, Douglas M ^b   Gorgas, Gayle C ^b   Wunderlich, John R ^a   Smith, Franz O ^a   Hampson, Brian S ^b   Rosenberg, Steven A ^a   Dudley, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Aastrom Biosciences Inc   (United States)

Author keywords

Adoptive cell therapy; Closed system bioreactor; Rapid expansion; rhIL 2; Tumor infiltrating lymphocyte

Indexed keywords

INTERLEUKIN 2; OKT 3;

ARTICLE; BIOREACTOR; CELL COUNT; CELL CULTURE; CELL GROWTH; GAS PERMEABILITY; LYMPHOCYTE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

BIOREACTORS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; PERFUSION; PHENOTYPE;

EID: 65749108349     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.04.009     Document Type: Article

References (16)

1. Brand K.A., and Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11 (1997) 388
2. Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., and Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26 (2003) 332
3. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., and Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008) 5233
4. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., and Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115 (2005) 1616
5. Guardino A.E., Rajapaksa R., Ong K.H., Sheehan K., and Levy R. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 8 (2006) 277
6. Hami L.S., Green C., Leshinsky N., Markham E., Miller K., and Craig S. GMP production and testing of Xcellerated T cells for the treatment of patients with CLL. Cytotherapy 6 (2004) 554
7. Knazek R.A., Wu Y.W., Aebersold P.M., and Rosenberg S.A. Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J. Immunol. Methods 127 (1990) 29
8. Koller M.R., Emerson S.G., and Palsson B.O. Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 82 (1993) 378
9. Koller M.R., Manchel I., Maher R.J., Goltry K.L., Armstrong R.D., and Smith A.K. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplant. 21 (1998) 653
10. Krauss S., Brand M.D., and Buttgereit F. Signaling takes a breath - new quantitative perspectives on bioenergetics and signal transduction. Immunity 15 (2001) 497
11. Levine B.L. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin. Biol. Ther. 8 (2008) 475
12. Powell Jr. D.J., Dudley M.E., Robbins P.F., and Rosenberg S.A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105 (2005) 241
13. Riddell S.R., and Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128 (1990) 189
14. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev., Cancer 8 (2008) 299
15. Tran C.A., Burton L., Russom D., Wagner J.R., Jensen M.C., Forman S.J., and DiGiusto D.L. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. J. Immunother. 30 (2007) 644
16. Tran K.Q., Zhou J., Durflinger K.H., Langhan M.M., Shelton T.E., Wunderlich J.R., Robbins P.F., Rosenberg S.A., and Dudley M.E. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31 (2008) 742